RESUMO
Platelet-rich plasma (PRP) is a promising treatment in regenerative medicine for androgenetic alopecia (AGA). PRP, derived from the patient's blood, contains a concentrated platelet fraction rich in growth factors and bioactive molecules that aid in tissue repair and wound healing. When PRP is administered, these factors are released, stimulating hair growth and regeneration. PRP's mechanism of action involves the release of growth factors like PDGF, TGF-β, VEGF, and IGF, which promote cell proliferation, activate dormant hair follicles, and induce hair cycle growth. PRP also reduces inammation, promotes angiogenesis, and may inhibit 5-alpha reductase activity, which contributes to AGA. By understanding these mechanisms, PRP can be optimized for effective hair restoration therapies in AGA
RESUMO
Mucopolysaccharidosis type II, also known as Hunter syndrome, is a rare, progressive, multisystemic lysosomal storage disease caused by de?ciency of iduronate 2 sulfatase, an enzyme responsible for the degradation of the mucopolysaccharides dermatan (DS) and keratan sulfate (QS), causing their accumulation at the lysosomal level. It is an X-linked disease, therefore it is common to ?nd most cases in men, rarely in women, it is considered an orphan disease given an incidence of approximately 1/100,000 live births. Various phenotypes of severe (2/3) and attenuated disease have been described. The diagnosis is based on clinical ?ndings and the measurement of mucopolysaccharides DS and QS in urine, which are elevated, con?rmed by determining the enzyme de?ciency in serum, leukocytes and ?broblasts. It has been observed that in patients with enzyme replacement therapy somatic symptoms have decreased, however there are several studies of alternative therapies in the future, including gene therapy as an alternative in the future